ZA201904616B - Glp-1 receptor agonists and uses thereof - Google Patents
Glp-1 receptor agonists and uses thereofInfo
- Publication number
- ZA201904616B ZA201904616B ZA2019/04616A ZA201904616A ZA201904616B ZA 201904616 B ZA201904616 B ZA 201904616B ZA 2019/04616 A ZA2019/04616 A ZA 2019/04616A ZA 201904616 A ZA201904616 A ZA 201904616A ZA 201904616 B ZA201904616 B ZA 201904616B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp
- receptor agonists
- agonists
- receptor
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435533P | 2016-12-16 | 2016-12-16 | |
| PCT/IB2017/057577 WO2018109607A1 (en) | 2016-12-16 | 2017-12-01 | Glp-1 receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201904616B true ZA201904616B (en) | 2021-05-26 |
Family
ID=60702906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/04616A ZA201904616B (en) | 2016-12-16 | 2019-07-15 | Glp-1 receptor agonists and uses thereof |
Country Status (41)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843888B (en) | 2016-10-24 | 2022-03-01 | 阿斯利康(瑞典)有限公司 | 6, 7, 8, 9-tetrahydro-3H-pyrazolo [4, 3-f ] isoquinoline derivatives useful for the treatment of cancer |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| AU2017374860B2 (en) | 2016-12-16 | 2021-09-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| TWI831738B (en) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
| PE20191105A1 (en) | 2016-12-16 | 2019-08-23 | Janssen Pharmaceutica Nv | INHIBITORS OF SMALL MOLECULES OF THE JAK KINAS FAMILY |
| MX2019008438A (en) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Estrogen receptor modulators. |
| JP7391046B2 (en) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Fused pyrimidine derivatives as A2A/A2B inhibitors |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| JP7498122B2 (en) | 2018-06-15 | 2024-06-11 | リアタ ファーマシューティカルズ インコーポレイテッド | Pyrazole and imidazole compounds for inhibition of IL-17 and RORγ |
| BR112020024956A2 (en) * | 2018-06-15 | 2021-03-09 | Pfizer Inc. | GLP-1 RECEPTOR AGONISTS AND USES OF THE SAME |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the JAK kinase family |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| BR112021000075A2 (en) | 2018-07-05 | 2021-04-06 | Incyte Corporation | PIRAZINE DERIVATIVES MELTED AS A2A / A2B INHIBITORS |
| CA3110601C (en) | 2018-08-31 | 2023-09-05 | Pfizer Inc. | Combinations for treatment of nash/nafld and related diseases |
| IL283322B1 (en) * | 2018-11-22 | 2025-04-01 | Qilu Regor Therapeutics Inc | Glp-1r agonists and uses thereof |
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
| TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
| PE20220143A1 (en) * | 2019-04-12 | 2022-01-27 | Qilu Regor Therapeutics Inc | GLP-1R AGONISTS AND USES THEREOF |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| EP3963329A1 (en) | 2019-04-29 | 2022-03-09 | Confo Therapeutics N.V. | Screening methods and assays for use with transmembrane proteins, in particular with gpcrs |
| EP4578460A2 (en) * | 2019-05-20 | 2025-07-02 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (en) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | Glucagon-like peptide 1 receptor agonists |
| US20220363673A1 (en) | 2019-06-28 | 2022-11-17 | Pfizer Inc. | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases |
| TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
| WO2021018023A1 (en) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Small molecule glp-1 receptor modulator |
| PH12022550605A1 (en) | 2019-09-13 | 2023-09-25 | Nimbus Saturn Inc | Hpk1 antagonists and uses thereof |
| TWI771766B (en) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | Diacylglycerol acyltransferase 2 inhibitor |
| CA3157525A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PH12022551181A1 (en) * | 2019-11-15 | 2023-04-03 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| KR20210059584A (en) * | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 receptor agonist and use thereof |
| ES3010351T3 (en) * | 2019-12-02 | 2025-04-02 | Hyundai Pharm Co Ltd | Glp-1 receptor agonist |
| KR20220112811A (en) * | 2019-12-10 | 2022-08-11 | 화이자 인코포레이티드 | 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl )methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxy Solid form of methyl)propan-2-amine salt |
| KR102635237B1 (en) * | 2019-12-10 | 2024-02-13 | 일라이 릴리 앤드 캄파니 | Methods and intermediates for the preparation of oxetan-2-ylmethanamine |
| EP4523751A3 (en) | 2020-01-29 | 2025-05-28 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PE20231066A1 (en) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| JP2023515404A (en) * | 2020-02-13 | 2023-04-13 | ガシャーブラム・バイオ・インコーポレイテッド | heterocyclic GLP-1 agonists |
| JP2021134211A (en) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Combinations for the treatment of NAFLD / NASH and related diseases |
| JP2022058085A (en) | 2020-02-24 | 2022-04-11 | ファイザー・インク | Combination of diacylglycerol acyltransferase 2 inhibitor and acetyl-CoA carboxylase inhibitor |
| EP4119555A4 (en) * | 2020-03-18 | 2023-08-23 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| US20230203021A1 (en) * | 2020-03-18 | 2023-06-29 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| IL296694A (en) | 2020-03-27 | 2022-11-01 | Pfizer | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| TW202144340A (en) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused imidazole derivatives, preparation method and medical use thereof |
| CN113493447B (en) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | GLP-1 receptor agonists |
| CN120267673A (en) | 2020-04-24 | 2025-07-08 | 阿斯利康(瑞典)有限公司 | Dosage regimens for treating cancer |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| FI4157832T3 (en) | 2020-05-27 | 2024-08-29 | Qilu Regor Therapeutics Inc | Salt and crystal forms of glp-1r agonists and uses thereof |
| IL298753B2 (en) | 2020-06-04 | 2024-05-01 | Hangzhou Sciwind Biosciences Co Ltd | A pentavalent heteroaromatic imidazole compound and its use |
| HUE068344T2 (en) | 2020-06-09 | 2024-12-28 | Pfizer | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof |
| US20230234968A1 (en) * | 2020-06-10 | 2023-07-27 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| CN117645601A (en) * | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | GLP-1 small molecule with cardiovascular benefit |
| TW202214610A (en) * | 2020-06-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 6-oxo-3,6-dihydropyridine derivative, preparation method thereof, and medical use thereof |
| CN113816948B (en) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | Condensed imidazole derivative, preparation method and medical application thereof |
| WO2021259309A1 (en) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1 receptor agonist, and pharmaceutical composition and use thereof |
| WO2022031994A1 (en) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| TW202220973A (en) * | 2020-08-06 | 2022-06-01 | 美商迦舒布魯姆生物有限公司 | Heterocyclic glp-1 agonists |
| CN116507326A (en) * | 2020-08-21 | 2023-07-28 | 拓臻制药公司 | Compounds that are GLP-1R agonists |
| CN116406360A (en) * | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
| KR20230058660A (en) | 2020-09-01 | 2023-05-03 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Fused imidazole derivatives, methods for their preparation, and their medical uses |
| KR20230093251A (en) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Antibody fragment against FAP |
| CN115515956B (en) * | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative, and preparation method and medical application thereof |
| CN116348464A (en) * | 2020-10-12 | 2023-06-27 | 杭州中美华东制药有限公司 | Benzimidazolone GLP-1 receptor agonists and uses thereof |
| US20230391760A1 (en) * | 2020-10-13 | 2023-12-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116547278A (en) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
| CN116710446B (en) * | 2020-10-14 | 2024-10-18 | 上海齐鲁锐格医药研发有限公司 | Crystal forms of GLP-1R agonists and their uses |
| CN114478497B (en) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | Arylalkyl acid GLP-1 receptor agonists and uses thereof |
| EP4247804A1 (en) * | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CN115461334B (en) * | 2020-11-27 | 2024-06-21 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative, and preparation method and medical application thereof |
| CN114591308B (en) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | GLP-1R receptor agonist compounds and application thereof |
| US20220193063A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Metabolites of glp1r agonists |
| US12065434B2 (en) * | 2020-12-15 | 2024-08-20 | Pfizer Inc. | Metabolites of GLP1R agonists |
| KR20230124956A (en) * | 2020-12-25 | 2023-08-28 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 5-membered ring derivatives and their medical uses |
| US20230089073A1 (en) * | 2021-01-28 | 2023-03-23 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022174253A1 (en) | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| JP2024509192A (en) | 2021-03-05 | 2024-02-29 | ニンバス サターン， インコーポレイテッド | HPK1 antagonists and their uses |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| JPWO2022202864A1 (en) | 2021-03-24 | 2022-09-29 | ||
| JP2024513011A (en) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | HPK1 antagonists and their uses |
| IL306110A (en) * | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| US20220396569A1 (en) * | 2021-05-03 | 2022-12-15 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (en) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | Glucagon-like peptide 1 receptor agonists |
| JP2024523525A (en) | 2021-06-24 | 2024-06-28 | 杭州中美華東製薬有限公司 | GLP-1 RECEPTOR AGONISTS AND COMPOSITIONS AND USES THEREOF - Patent application |
| US20240382471A1 (en) * | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (en) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and application thereof |
| CN117693504A (en) * | 2021-08-02 | 2024-03-12 | 深圳信立泰药业股份有限公司 | Salt of GLP-1R agonist compound, preparation method and medical application thereof |
| AU2022321506A1 (en) * | 2021-08-04 | 2024-02-01 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| US20250066337A1 (en) | 2021-08-26 | 2025-02-27 | Pfizer Inc. | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide |
| BR112024002129A2 (en) * | 2021-08-31 | 2024-04-30 | Pfizer | SOLID FORMS OF ACID 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2 -ILMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT |
| CN113548982B (en) * | 2021-09-03 | 2022-05-06 | 上海三牧化工技术有限公司 | Preparation method of 4-cyano-2-fluorobenzyl alcohol |
| WO2023038039A1 (en) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| TW202322806A (en) * | 2021-09-27 | 2023-06-16 | 美商拓臻製藥公司 | Compounds as glp-1r agonists |
| CA3233131A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| TWI843243B (en) * | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | Compounds as glp-1 receptor agonist, pharmaceutical composition including the same and use thereof |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| CR20240183A (en) | 2021-12-01 | 2024-06-07 | Pfizer | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
| AU2022401795A1 (en) * | 2021-12-03 | 2024-07-04 | Hangzhou Sciwind Biosciences Co., Ltd. | Crystal forms of thienoimidazole compound and preparation method thereof |
| JP2024544021A (en) | 2021-12-06 | 2024-11-26 | ファイザー・インク | Melanocortin 4 receptor antagonists and their uses - Patents.com |
| WO2023106310A1 (en) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Aromatic heterocyclic derivative having glp-1 receptor agonist activity |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN118434745A (en) * | 2021-12-29 | 2024-08-02 | 西藏海思科制药有限公司 | Salt of GLP-1 agonist, crystal form thereof and application thereof in medicine |
| CN118613476A (en) * | 2022-01-10 | 2024-09-06 | 西藏海思科制药有限公司 | A GLP-1 agonist salt and its crystal form and its application in medicine |
| WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| JP2025506474A (en) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | Heterocyclic GLP-1 agonists |
| IL315151A (en) * | 2022-02-23 | 2024-10-01 | Terns Pharmaceuticals Inc | Compounds as GLP-1R agonists |
| EP4491625A1 (en) | 2022-03-08 | 2025-01-15 | Guangzhou Unirise Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| EP4490155A1 (en) * | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| CN119255988A (en) | 2022-04-14 | 2025-01-03 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN119584994A (en) | 2022-05-02 | 2025-03-07 | 普雷西里克斯公司 | Pretargeting |
| CN116903588B (en) * | 2022-07-18 | 2025-03-21 | 厦门市博瑞来医药科技有限公司 | Pentavalent and hexavalent compounds, intermediates thereof, preparation methods, compositions and applications |
| WO2024018395A1 (en) * | 2022-07-22 | 2024-01-25 | Pfizer Inc. | Methods and intermediates for preparing 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| CN115536638B (en) * | 2022-08-15 | 2023-10-13 | 上海交通大学 | Triazole compound and application thereof |
| WO2024051700A1 (en) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | Novel aryl deuterated benzyl ether substituted heterocyclic compound as glp1r agonist |
| EP4585593A1 (en) * | 2022-09-06 | 2025-07-16 | Minidrank Therapeutics (Suzhou) New Drug Research and Development Co., Ltd | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof |
| JP2025084137A (en) | 2022-09-22 | 2025-06-03 | 塩野義製薬株式会社 | Fused ring compound having GLP-1 receptor agonist activity |
| WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
| WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| AU2023377707A1 (en) | 2022-11-11 | 2025-05-15 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| AU2023379473A1 (en) | 2022-11-16 | 2025-05-15 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024125446A1 (en) * | 2022-12-13 | 2024-06-20 | 杭州中美华东制药有限公司 | Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| WO2024127297A1 (en) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| CN118344349A (en) * | 2023-01-13 | 2024-07-16 | 中国科学院上海药物研究所 | 4-Alkoxybenzimidazole-6-carboxylic acid derivatives as GLP-1 receptor agonists |
| WO2024160271A1 (en) * | 2023-02-02 | 2024-08-08 | 江苏豪森药业集团有限公司 | Salt and crystal form of cycloalkene compound, and preparation method therefor and use thereof |
| WO2024169773A1 (en) * | 2023-02-14 | 2024-08-22 | 成都康弘药业集团股份有限公司 | Indazolinone compound, and preparation method therefor and use thereof |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024206647A1 (en) * | 2023-03-29 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Polymorphic forms and salts of a glp-1r agonist |
| WO2024212742A1 (en) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | Glp-1r agonist, preparation method therefor and use thereof |
| WO2024214038A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| CN118812522A (en) * | 2023-04-21 | 2024-10-22 | 苏州闻泰医药科技有限公司 | A GLP-1R receptor agonist compound salt, its crystal form, its preparation method and application |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| CN116675680B (en) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | Deuterated compound and preparation method, medicine and application thereof |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202515865A (en) * | 2023-09-21 | 2025-04-16 | 南韓商尹諾衛醫藥有限公司 | Method for preparing substituted fused imidazole derivative |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025104668A1 (en) | 2023-11-17 | 2025-05-22 | Pfizer Inc. | Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025140532A1 (en) * | 2023-12-27 | 2025-07-03 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2025140533A1 (en) * | 2023-12-27 | 2025-07-03 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH08508030A (en) | 1993-03-18 | 1996-08-27 | メルク シヤープ エンド ドーム リミテツド | Benzimidazole derivative |
| GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| SE0100903D0 (en) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US20040127504A1 (en) * | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| EP1939194A4 (en) * | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| SG10201401169QA (en) | 2009-04-02 | 2014-05-29 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| PE20130576A1 (en) * | 2010-05-13 | 2013-05-19 | Amgen Inc | HELPFUL HETEROCYCLIC NITROGEN COMPOUNDS AS PDE10 INHIBITORS |
| BR112013021236B1 (en) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | benzimidazole derivative compound, and, composition |
| AU2017374860B2 (en) | 2016-12-16 | 2021-09-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
-
2017
- 2017-12-01 AU AU2017374860A patent/AU2017374860B2/en active Active
- 2017-12-01 FI FIEP17817174.0T patent/FI3555064T3/en active
- 2017-12-01 BR BR112019012211-7A patent/BR112019012211A2/en active Search and Examination
- 2017-12-01 MY MYPI2019003381A patent/MY195385A/en unknown
- 2017-12-01 RU RU2019118485A patent/RU2740135C1/en active
- 2017-12-01 CN CN201780086550.1A patent/CN110325530B/en active Active
- 2017-12-01 HR HRP20221437TT patent/HRP20221437T1/en unknown
- 2017-12-01 PL PL17817174.0T patent/PL3555064T3/en unknown
- 2017-12-01 DK DK17817174.0T patent/DK3555064T5/en active
- 2017-12-01 KR KR1020217032471A patent/KR102466418B1/en active Active
- 2017-12-01 GE GEAP201715110A patent/GEP20217265B/en unknown
- 2017-12-01 ES ES17817174T patent/ES2934789T3/en active Active
- 2017-12-01 LT LTEPPCT/IB2017/057577T patent/LT3555064T/en unknown
- 2017-12-01 WO PCT/IB2017/057577 patent/WO2018109607A1/en active IP Right Grant
- 2017-12-01 UA UAA201906738A patent/UA122035C2/en unknown
- 2017-12-01 MD MDE20191184T patent/MD3555064T2/en unknown
- 2017-12-01 MA MA56480A patent/MA56480B1/en unknown
- 2017-12-01 EP EP17817174.0A patent/EP3555064B9/en active Active
- 2017-12-01 CU CU2019000056A patent/CU24573B1/en unknown
- 2017-12-01 KR KR1020197020714A patent/KR102314286B1/en active Active
- 2017-12-01 PE PE2019001229A patent/PE20191501A1/en unknown
- 2017-12-01 RS RS20221178A patent/RS63849B9/en unknown
- 2017-12-01 MX MX2019007077A patent/MX387259B/en unknown
- 2017-12-01 JP JP2019531391A patent/JP6637641B1/en active Active
- 2017-12-01 EA EA201991193A patent/EA037318B1/en unknown
- 2017-12-01 PH PH1/2019/501360A patent/PH12019501360B1/en unknown
- 2017-12-01 SI SI201731287T patent/SI3555064T1/en unknown
- 2017-12-01 CR CR20190289A patent/CR20190289A/en unknown
- 2017-12-01 PT PT178171740T patent/PT3555064T/en unknown
- 2017-12-01 HU HUE17817174A patent/HUE060533T2/en unknown
- 2017-12-13 TW TW106143701A patent/TWI713809B/en active
- 2017-12-13 US US15/839,901 patent/US10208019B2/en active Active
- 2017-12-13 CA CA2988721A patent/CA2988721C/en active Active
- 2017-12-14 UY UY0001037514A patent/UY37514A/en not_active Application Discontinuation
- 2017-12-15 AR ARP170103545A patent/AR110387A1/en unknown
-
2018
- 2018-12-14 US US16/220,184 patent/US10669259B2/en active Active
-
2019
- 2019-06-07 EC ECSENADI201941071A patent/ECSP19041071A/en unknown
- 2019-06-11 CO CONC2019/0006046A patent/CO2019006046A2/en unknown
- 2019-06-12 IL IL267288A patent/IL267288B/en active IP Right Grant
- 2019-06-14 DO DO2019000166A patent/DOP2019000166A/en unknown
- 2019-06-14 CL CL2019001651A patent/CL2019001651A1/en unknown
- 2019-07-15 ZA ZA2019/04616A patent/ZA201904616B/en unknown
- 2019-12-20 JP JP2019230341A patent/JP6982054B2/en active Active
-
2020
- 2020-04-29 US US16/861,646 patent/US10851081B2/en active Active
- 2020-10-30 US US17/085,534 patent/US11512070B2/en active Active
-
2022
- 2022-10-24 US US18/049,052 patent/US11802121B2/en active Active
- 2022-12-22 CY CY20221100805T patent/CY1125716T1/en unknown
-
2023
- 2023-09-28 US US18/477,050 patent/US12319669B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904616B (en) | Glp-1 receptor agonists and uses thereof | |
| IL279300A (en) | Glp-1 receptor agonists and uses thereof | |
| IL279224A (en) | Glp-1 receptor agonists and uses thereof | |
| ZA201801750B (en) | Farnesoid x receptor agonists and uses thereof | |
| ZA201802371B (en) | Glucagon receptor agonists | |
| IL267436A (en) | Novel tnfr agonists and uses thereof | |
| IL251741A0 (en) | Co-agonists of the glucagon and glp-1 receptors | |
| GB201520191D0 (en) | T-cell receptor and uses thereof | |
| GB201811757D0 (en) | Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof | |
| PL3347376T3 (en) | Novel igfr-like receptor and uses thereof | |
| HK1233666A1 (en) | Fgf21 receptor agonists and uses thereof |